Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02718911 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT02718911 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 72 participants.
The verdict
NCT02718911, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
- DRUG LY3022855
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2016-06-16 |
| Est. Completion | 2018-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02718911
The ClinicalTrials.gov registry entry for NCT02718911 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Durvalumab is the first listed.
NCT02718911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02718911 about?
NCT02718911 is a clinical study titled "A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors". The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.
What is the current status of trial NCT02718911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2016-06-16. Estimated completion is 2018-12-14.
What interventions are being tested in trial NCT02718911?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG), LY3022855 (DRUG).
Who is sponsoring clinical trial NCT02718911?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.